Abstract
Tricuspid regurgitation (TR) is a common finding in patients with left-sided valvular or myocardial disease. However, many patients with severe symptomatic TR are deemed inoperable or at high surgical risk, often due to comorbidities and the need for redo sternotomy. Thus, despite the poor prognosis associated with this condition, few patients undergo isolated surgical tricuspid valve repair. Therefore, there is an unmet clinical need for less invasive therapeutic options for these patients. In recent times, several transcatheter therapies have emerged for treating TR, with promising safety and preliminary efficacy results. In this review, we describe the main features of and clinical results associated with such devices, and describe the ongoing and future studies in the field.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
